8-K: Opus Genetics Announces Positive Phase 3 Results for Presbyopia Treatment, Paving Way for FDA Submission

Opus Genetics, Inc. announced positive topline results from its VEGA-3 Phase 3 trial for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia, meeting its primary and key secondary endpoints.

Summary

• Opus Genetics, Inc. announced positive topline results from its VEGA-3 Phase 3 trial evaluating Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia.
• The trial met its primary endpoint, with a statistically significant 27.2% of participants treated with the solution achieving a 15-letter improvement in binocular distance-corrected near visual acuity (DCNVA) with less than a 5-letter loss in binocular best-corrected distance visual acuity (BCDVA) at 12 hours post-dose on Day 8, compared to 11.5% of patients on placebo (p<0.0001).
• Key secondary efficacy endpoints were also met, reinforcing the observed benefit.
• The safety profile of Phentolamine Ophthalmic Solution 0.75% was consistent with previous clinical trials, with no treatment-related serious adverse events reported in the study.
• No evidence of tachyphylaxis was observed over the 6-week study period.
• The company plans to submit an application to the U.S. Food and Drug Administration (FDA) in the second half of 2025, supported by the positive results from both VEGA-2 and VEGA-3 trials.
• Opus Genetics expects its cash on hand to be sufficient to fund operations into the second half of fiscal year 2026.

Sentiment

Score: 9

Explanation: The announcement of positive topline results from a pivotal Phase 3 trial, meeting both primary and key secondary endpoints with a favorable safety profile and no tachyphylaxis, is a highly significant positive development for a biopharmaceutical company, paving the way for regulatory submission.

Positives

• The VEGA-3 Phase 3 trial met its primary endpoint with statistical significance (p<0.0001).
• 27.2% of participants treated with Phentolamine Ophthalmic Solution 0.75% achieved a 15-letter improvement in DCNVA with less than a 5-letter loss in BCDVA, significantly higher than 11.5% for placebo.
• Key secondary efficacy endpoints were also met, reinforcing the benefit observed.
• Rapid improvement was demonstrated, with 20.6% of patients achieving a 15-letter ETDRS (3-line) gain in DCNVA at 1-hour post-dose on Day 1 compared to 6.1% of those receiving placebo (p=0.0002).
• Significant patient-reported functional benefit was observed at Days 3 and 8 and Week 6, with patients reporting satisfaction with near vision upon awakening (p<0.0001) and improvement in their near vision (p<0.0001).
• The safety profile was consistent with previous trials, with no new safety signals identified and no treatment-related serious adverse events reported.
• No evidence of tachyphylaxis was observed after 6 weeks, indicating sustained efficacy.
• The positive results from both Phase 3 VEGA-2 and VEGA-3 trials support the planned submission of an application to the U.S. Food and Drug Administration (FDA).

Negatives

• The most common (≥5%) treatment-emergent adverse events included conjunctival hyperemia, instillation site irritation, and dysgeusia, although these were predominantly mild.
• A low rate of headache (2.6%) was reported over the study period.

Risks

• Actual business, prospects, and results of operations could differ materially from forward-looking statements due to various factors and events.
• Factors that could cause differences include those described under the heading 'Risk Factors' in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and in other filings with the U.S. Securities and Exchange Commission.
• Forward-looking statements are based upon current expectations and involve assumptions that may never materialize or may prove to be incorrect.

Future Outlook

Opus Genetics plans to submit an application to the U.S. Food and Drug Administration (FDA) for Phentolamine Ophthalmic Solution 0.75% in the second half of 2025, following positive results from both VEGA-2 and VEGA-3 trials. The company anticipates its current cash on hand will be sufficient to fund operations into the second half of fiscal year 2026.

Management Comments

• "The results of the VEGA-3 trial reinforce our belief that Phentolamine Ophthalmic Solution 0.75% could offer an option to improve near vision for millions of adults affected by presbyopia." George Magrath, M.D., CEO, Opus Genetics.
• "The positive results from both our Phase 3 VEGA-2 and VEGA-3 trials support the submission of an application to the U.S. Food and Drug Administration (FDA), which we plan to file in the second half of 2025." George Magrath, M.D., CEO, Opus Genetics.
• "These findings provide further validation of Phentolamine Ophthalmic Solution 0.75% as a differentiated approach to managing presbyopia, reflected by its ability to improve near vision while preserving distance vision without compromising low contrast vision." Jay Pepose, M.D., Ph.D., Chief Medical Advisor, Opus Genetics.

Industry Context

Presbyopia is a highly prevalent ophthalmic disorder, affecting an estimated 128 million Americans and over 2 billion people worldwide, with its incidence expected to grow with an aging population. Phentolamine Ophthalmic Solution 0.75% offers a non-surgical, eye-drop based treatment, potentially addressing a significant unmet medical need in this large market. Opus Genetics' broader focus on gene therapies for inherited retinal diseases positions it as a key player in the ophthalmology therapeutic area.

Comparison to Industry Standards

• NA

Related Party Transactions

• Opus Genetics and Viatris (through its affiliate) are parties to a global licensing agreement for the development of Phentolamine Ophthalmic Solution 0.75%.
• The agreement grants exclusive rights to Viatris to commercialize Phentolamine Ophthalmic Solution 0.75% in the United States.

Stakeholder Impact

• Shareholders: Positive clinical trial results and planned FDA submission are highly likely to increase shareholder value and confidence in the company's pipeline.
• Patients (Customers): The positive trial results indicate a potential new, effective, and well-tolerated treatment option for presbyopia, addressing a significant unmet need.
• Employees: The successful trial validates the company's research and development efforts, potentially leading to increased job security and future growth opportunities.
• Partners (Viatris): The positive results strengthen the commercialization prospects for Viatris, who holds exclusive U.S. commercialization rights for Phentolamine Ophthalmic Solution 0.75%.

Next Steps

• Submission of an application to the U.S. Food and Drug Administration (FDA) for Phentolamine Ophthalmic Solution 0.75% in the second half of 2025.
• Continued monitoring of VEGA-3 patients for long-term safety over 48 weeks.
• Hosting a webcast and conference call to discuss the VEGA-3 results and provide a corporate update.

Key Dates

Recommendation

Keywords

Opus Genetics, Phentolamine Ophthalmic Solution, Presbyopia, VEGA-3, Phase 3 trial, clinical trial results, ophthalmology, biopharmaceutical, FDA submission, cash runway, inherited retinal diseases, gene therapy